The Floxed p53 Mouse was developed in the laboratory of Dr. Anton Berns of the Netherlands Cancer Institute (NKI). The Trp53 mutation was generated by insertion of loxP sites flanking exons 2 through 10. IB10/E15B10 (129P2) embryonic stem cells were targeted and the resulting chimeras were backcrossed to C57BL/6. Taconic received stock in 2011. The line was derived by embryotransfer and backcrossed five generations (N5) to C57BL/6NTac . The line was maintained by incrossing mice homozygous for the floxed allele.
Jonkers J, Meuwissen R, van der Gulden H, Peterse H, van der Valk M, Berns A. (2001) Synergistic tumor suppressor activity of BRCA2 and p53 in a conditional mouse model for breast cancer. Nat Genet. 29(4):418-25.